Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Biomarker-Driven Early Clinical Trials in Oncology: A Paradigm Shift in Drug Development

Tan, Daniel S. W. BSc (Hons), MRCP; Thomas, George V. MRCPI, MD‡§; Garrett, Michelle D. BSc (Hons), PhD*; Banerji, Udai MD, MRCP, PhD*†; de Bono, Johann S. MD, FRCP, MSc, PhD*†; Kaye, Stan B. BSc, MD, FRCP, FRCR, FRSE, FMedSci*†; Workman, Paul BSc (Hons), PhD, DSc (Hon), FMedSci, FIBiol*

doi: 10.1097/PPO.0b013e3181bd0445
Special Issue on Monitoring of Therapeutic Responses to Cancer Treatment: Review Article
Buy

Early clinical trials represent a crucial bridge between preclinical drug discovery and the especially resource-intense randomized phase III trial—the definitive regulatory hurdle for drug approval. High attrition rates and rising costs, when coupled with the extraordinary opportunities opened up by cancer genomics and the promise of personalized medicine call for new approaches in the conduct and design of phase I/II trials. The key challenge lies in increasing the odds for successful and efficient transition of a compound through the drug development pipeline. The incorporation of scientifically and analytically validated biomarkers into rationally designed hypothesis-testing clinical trials offers a promising way forward to achieving this objective. In this article, we provide an overview of biomarkers in early clinical trials, including examples where they have been particularly successful, and the caveats and pitfalls associated with indiscriminate application. We describe the use of pharmacodynamic end points to demonstrate the proof of modulation of target, pathway, and biologic effect, as well as predictive biomarkers for patient selection and trial enrichment. Establishing the pharmacologic audit trail provides a means to assess and manage risk in a drug development program and thus increases the rationality of the decision-making process. Accurate preclinical models are important for pharmacokinetic-pharmacodynamic-efficacy modeling and biomarker validation. The degree of scientific and analytical validation should ensure that biomarkers are fit-for purpose, according to the stage of development and the impact on the trial; specifically they are either exploratory or used to make decisions within the trial. To be maximally useful at an early stage, these must be in place before the commencement of phase I trials. Validation and qualification of biomarkers then continues through clinical development. We highlight the impact of modern technology platforms, such as genomics, proteomics, circulating tumor cells, and minimally invasive functional and molecular imaging, with respect to their potential role in improving the success rate and speed of drug development and in interrogating the consequences of therapeutic intervention and providing a unique insight into human disease biology. With these technologies already having an impact in the clinic today, we predict that further future advances will come from the application of network analysis to clinical trials, leading to individualized systems-based medicine for cancer.

From the *Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton; †Drug Development Unit, Section of Medicine, The Institute of Cancer Research and The Royal Marsden Hospital NHS Trust, Sutton; ‡Translational Molecular Oncology Team, Section of Cell and Molecular Biology, Chester Beatty Laboratories, London; and §Translational Molecular Oncology Team, Section of Medicine, The Institute of Cancer Research, Haddow Laboratories, Sutton, UK.

Supported in part by Cancer Research UK grant number C309/A8274 (to P.W.), NHS, Ministry of Health of Singapore (D.S.W.T.), and Medical Research Council Biomarkers grant (J.S.d.B.).

Paul Workman is a Cancer Research UK Life Fellow.

Daniel Tan is on a National Medical Research Council Fellowship.

All the authors are employees of The Institute of Cancer Research, which has a commercial interest in the development of inhibitors of HSP90, PI3 kinase, AKT, BRAF, PARP, CYP17, CDK, chromatin-modifying enzymes and other targets. The authors have potentially relevant commercial interactions with Vernalis Ltd, Novartis, Piramed Pharma (recently acquired by Roche), Genentech, Astex Therapeutics, AstraZeneca, GSK, Cougar Biotechnology Inc. (recently acquired by Johnson & Johnson) and Cyclacel Pharmaceuticals.

Reprints: Paul Workman, BSc (Hons), PhD, DSc (Hon), FMedSci, FIBiol, Cancer Research-UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, UK. E-mail: Paul.Workman@icr.ac.uk.

© 2009 Lippincott Williams & Wilkins, Inc.